A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances

Impact of cytochrome P450 genes on suicide attempt and risk

(2013) Eva M. Peñas-Lledó et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene

(2013) A Persson et al.   MOLECULAR PSYCHIATRY

The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder

(2012) Peter Höfer et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Suicidal phenotypes associated with family history of suicidal behavior and early traumatic experiences

(2012) J. Lopez-Castroman et al.   JOURNAL OF AFFECTIVE DISORDERS

Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function

(2012) J C Stingl et al.   MOLECULAR PSYCHIATRY

CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients

(2012) E M Peñas-LLedó et al.   MOLECULAR PSYCHIATRY

Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects

(2012) S C Sim et al.   PHARMACOGENOMICS JOURNAL

Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping ofCYP2C9,CYP2C19andCYP2D6genes

(2011) David Villagra et al.   Biomarkers in Medicine

CYP2D6 in the Brain: Impact on Suicidality

(2011) J C Stingl (formerly Kirchheiner) et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP

(2011) Patricia Huezo-Diaz et al.   JOURNAL OF PSYCHOPHARMACOLOGY

High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders

(2011) E M Peñas-Lledó et al.   MOLECULAR PSYCHIATRY

CYP2D6and the severity of suicide attempts

(2011) Eva M Peñas-Lledó et al.   PHARMACOGENOMICS

Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations

(2010) Rasmus S. Pedersen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Cytochrome P450 2D6 Phenotype Predicts Antidepressant Efficacy of Venlafaxine

(2010) Kasia W. Lobello et al.   JOURNAL OF CLINICAL PSYCHIATRY

CYP2C19 variation and citalopram response

(2010) David A. Mrazek et al.   Pharmacogenetics and Genomics

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response

(2010) Ming-Hsien Tsai et al.   PHARMACOGENOMICS

Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients

(2010) A de Vos et al.   PHARMACOGENOMICS JOURNAL

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans

(2010) A LLerena et al.   PHARMACOGENOMICS JOURNAL

High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases

(2009) A L Zackrisson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

(2009) Alessandro Serretti et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients

(2009) P W Schenk et al.   PHARMACOGENOMICS JOURNAL

The Impact of CYP2D6 and CYP2C19 Polymorphisms on Suicidal Behavior and Substance Abuse Disorder Among Patients With Schizophrenia: A Retrospective Study

(2009) Camilla J Kobylecki et al.   THERAPEUTIC DRUG MONITORING

Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients

(2008) I. Rudberg et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

(2008) Adrián LLerena et al.   PHARMACOGENOMICS